Tissue Manufacturing by Bioprinting: Challenges & Opportunities
Published: November 6, 2018Latest Advances in Bioprocessing: Overcoming Bottlenecks
Fabien Guillemot, Laurence Hutter, Bruno Brisson, Delphine Fayol & Bertrand Viellerobe
EXPERT INSIGHT
Despite substantial investments to meet clinical and commercial expectations, and while scientific achievements at the preclinical research stage have sometimes been impressive, scaffold-based tissue engineering approaches are struggling to find the way to therapeutic and industrial success. The main challenges for the manufacture of tissue-engineered Advance Therapy Medicinal Products (ATMPs) concern the improvement of the standardization of manufacturing processes, tissue functionality and cost–effectiveness and profitability of related treatments. Based on our experience in the field of bioprinting, we discuss how this technology – thanks to its characteristics resulting from the convergence of automation, biology and digital technology – should make it possible to overcome current tissue manufacturing bottlenecks and also provide new opportunities.
DOI: 10.18609/cgti.2018.081Citation: Cell Gene Therapy Insights 2018; 4(8), 781-790.
